目的 探讨注射用丹参多酚酸对急性缺血性脑卒中患者血清中超敏C反应蛋白（hs-CRP）、CD62P水平及短期预后的影响。方法 选取2017年7月—2020年12月保定市第一中心医院收治的符合入组标准的急性缺血性脑卒中患者200例为研究对象，采用随机数字表法分为试验组100例和对照组100例。对照组按照指南给予标准化治疗，试验组在对照组治疗的基础上静脉滴注注射用丹参多酚酸（0.13 g加入0.9%的氯化钠注射液250 mL），每天1次，两组均持续治疗14 d，观察两组治疗前、后血清中hs-CRP以及CD62P水平的变化以及美国国立卫生研究院脑卒中量表（NIHSS）评分的变化。结果 对照组2例脱落、共98例完成研究，试验组全部完成研究。治疗后，两组NIHSS评分均明显降低，同组治疗前后比较差异具有统计学意义（P＜0.05），且试验组NIHSS评分明显低于对照组（P＜0.05）；治疗后，两组患者血清中hs-CRP、CD62P的水平均明显降低，同组治疗前后比较差异具有统计学意义（P＜0.05），且试验组血清中hs-CRP、CD62P的水平显著低于对照组（P＜0.05）。结论 注射用丹参多酚酸可降低炎症因子（hs-CRP、CD62P）的水平，改善患者的生活质量，促进患者神经功能的恢复，有利于急性缺血性脑卒中患者的短期预后，且安全性较高，具有一定的临床应用价值。

Objective To investigate the effect of Salvianolic Acids for Injection (SAFI) on serum high-sensitivity C-reactive protein (hs-CRP), CD62P levels and short-term prognosis in patients with acute ischemic stroke. Methods A total of 200 patients with acute ischemic stroke who met the inclusion criteria and were admitted to the third department of neurology in the Baoding NO.1 Central Hospital from July 2017 to December 2020 were selected as the research objects. They were divided into the experimental group of 100 cases and the control group of 100 cases by random number table method. Patients in the control group were given standardized treatment according to the guidelines. Patients in the experimental group were given intravenous drip of SAFI, 0.13 g of 0.9% Sodium Chloride Injection 250 mL, once a day, on the basis of the standardized treatment. Both groups were treated continuously for 14 days. The changes of serum high sensitivity C-reactive protein (hs-CRP) and CD62P levels and the changes of the National Institutes of Health Stroke Scale (NIHSS) score before and after treatment in two groups. Results The control group had two cases of detachment, with a total of 98 cases completing the study, and the experimental group all completed the study. After treatment, the NIHSS scores of two groups were significantly decreased, and the difference was statistically significant in the same group before treatment (P＜0.05), and the NIHSS scores of the experimental group were also significantly lower than those of the control group (P＜0.05). The levels of hs-CRP and CD62P in serum were significantly decreased, and the difference was statistically significant in the same group before and after treatment (P＜0.05), and the levels of serum hs-CRP and CD62P in the experimental group were significantly lower than those in the control group (P＜0.05). Conclusions SAFI can reduce the level of inflammatory factors (hsCRP, CD62P), improve the quality of life of patients, promote the recovery of neurological function, and is beneficial to the shortterm prognosis of patients with acute ischemic stroke, certain clinical application value.

R286.1，R971

河北省医学研究重点课题计划项目（20181487）